CervoMed Q3 net loss narrows as R&D costs drop after completion of RewinD-LB trial

Overview

• US biotech's Q3 net loss narrowed and beat analyst expectations

• R&D expenses declined, mainly due to lower costs from completed clinical trials

• No grant revenue recognized in Q3, reflecting completion of prior trial funding

Outlook

• CervoMed aims to secure a partner to advance neflamapimod into Phase 3 DLB trial

• Company expects to present 24-week biomarker data in nfvPPA at CTAD 2026 later in November

• Topline data from Phase 2a RESTORE stroke trial expected by end of 2026

Result Drivers

• LOWER R&D COSTS - Co said reduced R&D expenses were mainly due to completion of the RewinD-LB trial and lower personnel and trial costs

• NO GRANT REVENUE - Co said absence of grant revenue reflected completion of prior trial funding

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for CervoMed Inc is $15.00, about 956.3% above its November 6 closing price of $1.42

Reuters Recommended Reads

• Nov 6 - Aligos Therapeutics Q3 net loss narrows on lower R&D costs

• Nov 9 - Editas Medicine Q3 net loss narrows

• Nov 6 - Soligenix Q3 net loss narrows on lower R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)